20th Sep 2023 11:42
Director Dealings
Oxford, UK - 20 September 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces the following share purchases by certain Directors and Senior management.
Name of PDMR | Number of ordinary shares purchased | Number of ordinary shares now held | Total number of ordinary shares held as a percentage of the Company's share capital |
Dr. Roch Doliveux | 36,130 | 371,805 | 0.385% |
Dr. Frank Mathias | 20,000 | 20,000 | 0.020% |
Stuart Paynter | 4,030 | 18,687 | 0.019% |
Leone Patterson | 5,849 | 5,849 | 0.0061% |
Catherine Moukheibir | 7,226 | 25,756 | 0.027% |
Stuart Henderson | 1,000 | 10,862 | 0.011% |
Sebastien Ribault* | 1,500 | - | - |
Nick Page* | 11,678 | - | - |
Matthew Treagus* | 3,842 | - | - |
James Miskin* | 1,808 | - | - |
*Senior Management
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Dr. Roch Doliveux | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Chairman
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
36,130
£99,104.59 | ||||
f) | Date of the transaction | 2023-09-20; 10:27 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Dr. Frank Mathias | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
20,000
£54,996 | ||||
f) | Date of the transaction | 2023-09-20; 10:26 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Stuart Paynter | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
4,030
£9,998.43 | ||||
f) | Date of the transaction | 2023-09-20; 08.01 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Leone Patterson | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Director
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
5,849
£16,052.58 | ||||
f) | Date of the transaction | 2023-09-20; 10:28 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Catherine Moukheibir | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Director
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
7,226
£19,820.92 | ||||
f) | Date of the transaction | 2023-09-20; 10:28 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Stuart Henderson | ||||
2. | Reason for the notification | |||||
a) | Position/status | Non-Executive Director
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
1,000
£2,749.70 | ||||
f) | Date of the transaction | 2023-09-20; 10:26 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Sebastien Ribault | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Commercial Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
1,500
£4,124.55 | ||||
f) | Date of the transaction | 2023-09-20; 10:27 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Nick Page | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Operations Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
11,678
£29,837.29 | ||||
f) | Date of the transaction | 2023-09-20; 08.08 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | Matthew Treagus | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Information Officer and Chief of Staff | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
3,842
£9,942.90 | ||||
f) | Date of the transaction | 2023-09-20; 08.05 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR") | |||||
a) | Name | James Miskin | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Technical Officer | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Purchase of shares | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s)
|
| ||||
e) | Aggregated information - Aggregate volume - Aggregated total
|
1,808
£4,953.92 | ||||
f) | Date of the transaction | 2023-09-20; 10:55 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
-Ends-
For further information, please contact: | |
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.
Related Shares:
Oxford Biomedica